Aldosterone and diabetic kidney disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Young Sun | - |
dc.contributor.author | Cha, Dae Ryong | - |
dc.date.accessioned | 2021-09-08T11:06:14Z | - |
dc.date.available | 2021-09-08T11:06:14Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2009-12 | - |
dc.identifier.issn | 1534-4827 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/118839 | - |
dc.description.abstract | Aldosterone plays an important role in salt and water homeostasis and blood pressure control through the classical mineralocorticoid receptor. However, recent findings of the mineralocorticoid receptor in nonepithelial tissues suggest that aldosterone may have additional functions. Significant evidence now exists suggesting that aldosterone directly induces tissue injury. Systemic or local aldosterone has emerged as a multifunctional hormone exhibiting profibrotic and proinflammatory actions that extend beyond the classical hemodynamic effect. The incomplete blockade of the renin-angiotensin-aldosterone system by angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has led to experimental and clinical efforts using aldosterone inhibition. Recently, these efforts have provided us with an expanded understanding of a new pathogenic role for aldosterone in diabetic vascular complications. This article focuses on the role of aldosterone in the pathogenesis of diabetic kidney disease and recent important clinical data supporting the inhibition of aldosterone in treating diabetic kidney disease. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | CURRENT MEDICINE GROUP | - |
dc.subject | TISSUE GROWTH-FACTOR | - |
dc.subject | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | - |
dc.subject | RENAL MESANGIAL CELLS | - |
dc.subject | MINERALOCORTICOID RECEPTOR | - |
dc.subject | FACTOR-BETA | - |
dc.subject | COMBINATION TREATMENT | - |
dc.subject | HYPERTENSIVE-RATS | - |
dc.subject | FACTOR EXPRESSION | - |
dc.subject | ANGIOTENSIN-II | - |
dc.subject | SPIRONOLACTONE | - |
dc.title | Aldosterone and diabetic kidney disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Cha, Dae Ryong | - |
dc.identifier.doi | 10.1007/s11892-009-0074-x | - |
dc.identifier.scopusid | 2-s2.0-72849130429 | - |
dc.identifier.wosid | 000272181000007 | - |
dc.identifier.bibliographicCitation | CURRENT DIABETES REPORTS, v.9, no.6, pp.453 - 459 | - |
dc.relation.isPartOf | CURRENT DIABETES REPORTS | - |
dc.citation.title | CURRENT DIABETES REPORTS | - |
dc.citation.volume | 9 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 453 | - |
dc.citation.endPage | 459 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | TISSUE GROWTH-FACTOR | - |
dc.subject.keywordPlus | PLASMINOGEN-ACTIVATOR INHIBITOR-1 | - |
dc.subject.keywordPlus | RENAL MESANGIAL CELLS | - |
dc.subject.keywordPlus | MINERALOCORTICOID RECEPTOR | - |
dc.subject.keywordPlus | FACTOR-BETA | - |
dc.subject.keywordPlus | COMBINATION TREATMENT | - |
dc.subject.keywordPlus | HYPERTENSIVE-RATS | - |
dc.subject.keywordPlus | FACTOR EXPRESSION | - |
dc.subject.keywordPlus | ANGIOTENSIN-II | - |
dc.subject.keywordPlus | SPIRONOLACTONE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.